Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva launches Yaz generic in the US, triggering patent infringement suit by Bayer

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has launched its own generic version of Bayer's oral contraceptive, Yaz (drospirenone plus ethinyl estradiol), in the US to be sold under the brand-name Gianvi. The move immediately triggered a patent infringement lawsuit from Bayer, which has accused Teva of infringing three patents that expire in June 2014. Yaz is the top-selling birth control pill in the US.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts